Compugen Ltd
CGEN
Market Cap$167.77M
Close$
$2.54
33.1% upside
Current Fair Value
33.1% upsideUndervalued by 33.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $167.77 Million |
|---|---|
| Enterprise Value | $70.84 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.39 |
| Beta | 2.37 |
| Outstanding Shares | 89,237,465 |
| Avg 30 Day Volume | 308,512 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.98 |
|---|---|
| PEG | 134.11 |
| Price to Sales | - |
| Price to Book Ratio | 1.91 |
| Enterprise Value to Revenue | 11.81 |
| Enterprise Value to EBIT | -2.04 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...